Literature DB >> 20375998

ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis.

B Sassolas1, C Haddad, M Mockenhaupt, A Dunant, Y Liss, K Bork, U F Haustein, D Vieluf, J C Roujeau, H Le Louet.   

Abstract

Epidermal necrolysis (EN)--either Stevens-Johnson syndrome (SJS) or toxic EN (TEN)--is a severe drug reaction. We constructed and evaluated a specific algorithm, algorithm of drug causality for EN (ALDEN), in order to improve the individual assessment of drug causality in EN. ALDEN causality scores were compared with those from the French pharmacovigilance method in 100 cases and the case-control results of the EuroSCAR study. Scores attributed by ALDEN segregated widely. ALDEN pointed to a "probable" or "very probable" causality in 69/100 cases as compared to 23/100 with the French method (P < 0.001). It scored "very unlikely" causality for 64% of medications vs. none with the French method. Results of ALDEN scores were strongly correlated with those of the EuroSCAR case-control analysis for drugs associated with EN (r = 0.90, P < 0.0001), with probable causality being reported in 218/329 exposures. ALDEN excluded causality in 321 drugs that the case-control analysis had described as "probably not associated" and in 22/233 drugs that had been described as inconclusive exposures. Being more sensitive than a general method, ALDEN, which correlates well with case-control analysis results, can be considered a reference tool in SJS/TEN.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20375998     DOI: 10.1038/clpt.2009.252

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  121 in total

1.  Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy.

Authors:  Lisa M Wheatley; Marshall Plaut; Julie M Schwaninger; Aleena Banerji; Mariana Castells; Fred D Finkelman; Gerald J Gleich; Emma Guttman-Yassky; Simon A K Mallal; Dean J Naisbitt; David A Ostrov; Elizabeth J Phillips; Werner J Pichler; Thomas A E Platts-Mills; Jean-Claude Roujeau; Lawrence B Schwartz; Lauren A Trepanier
Journal:  J Allergy Clin Immunol       Date:  2015-08       Impact factor: 10.793

Review 2.  Toxic Epidermal Necrolysis and Steven-Johnson Syndrome: A Comprehensive Review.

Authors:  Olivia A Charlton; Victoria Harris; Kevin Phan; Erin Mewton; Chris Jackson; Alan Cooper
Journal:  Adv Wound Care (New Rochelle)       Date:  2020-01-09       Impact factor: 4.730

3.  Stevens-Johnson syndrome/toxic epidermal necrolysis: are drug dictionaries correctly informing physicians regarding the risk?

Authors:  Cynthia Haddad; Alexis Sidoroff; Sylvia H Kardaun; Maja Mockenhaupt; Daniel Creamer; Ariane Dunant; Jean-Claude Roujeau
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

4.  Risk of toxic epidermal necrolysis and Stevens-Johnson syndrome associated with benzodiazepines: a population-based cohort study.

Authors:  Elisa Martín-Merino; Francisco J de Abajo; Miguel Gil
Journal:  Eur J Clin Pharmacol       Date:  2015-05-05       Impact factor: 2.953

5.  Allopurinol induced stevens - johnson syndrome - a case report.

Authors:  Sabyasachi Paik; Sukanta Sen; Joydip Das; Bibhuti Saha; Santanu K Tripathi
Journal:  J Clin Diagn Res       Date:  2015-02-01

6.  Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case-Control Study.

Authors:  Noel Frey; Michael Bodmer; Andreas Bircher; Susan S Jick; Christoph R Meier; Julia Spoendlin
Journal:  Drug Saf       Date:  2019-01       Impact factor: 5.606

7.  Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Associated with Carbonic Anhydrase Inhibitors: Epidemiology, Genetics, and Insights into Mechanisms.

Authors:  Jason A Trubiano; David A Ostrov; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2019 Nov - Dec

Review 8.  [Dermatological conditions requiring intensive care].

Authors:  C Marks; R Marks
Journal:  Hautarzt       Date:  2012-09       Impact factor: 0.751

9.  Intentional rechallenge: does the benefit outweigh the risk?

Authors:  Vid Stanulović; Mauro Venegoni; Brian Edwards
Journal:  Drug Saf       Date:  2013-03       Impact factor: 5.606

10.  Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population.

Authors:  C-C Chang; C-C Ng; C-L Too; S-E Choon; C-K Lee; W-H Chung; S H Hussein; K-S Lim; S Murad
Journal:  Pharmacogenomics J       Date:  2016-03-01       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.